Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Annamycin in Refractory/Relapsed AML
NCT03388749Phase 2Completed
- Sponsor
- Moleculin Biotech, Inc.
- Start
- Dec 2018
- Primary completion
- Feb 2022
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of annamycin in acute myeloid leukemia (AML), sponsored by Moleculin Biotech, Inc.. Started Dec 2018; status: completed.
02
Drugs
annamycin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03388749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388749.